Literature DB >> 10985954

Delivery of a retroviral vector expressing human beta-glucuronidase to the liver and spleen decreases lysosomal storage in mucopolysaccharidosis VII mice.

C Gao1, M S Sands, M E Haskins, K P Ponder.   

Abstract

Mucopolysaccharidosis VII (MPS VII) is caused by beta-glucuronidase (beta-gluc) deficiency and results in lysosomal storage due to the inability to degrade glycosaminoglycans. Transfer of a beta-gluc gene into the liver reduces hepatic pathology as well as storage in other organs via uptake of secreted protein. A Moloney murine leukemia-based retroviral vector expressing the human beta-gluc cDNA was injected intravascularly into MPS VII mice during hepatocyte replication, which was induced with im injection of an adenoviral vector that transiently expressed hepatocyte growth factor (Ad.CMV. HGF). This procedure resulted in transduction of approximately 1% of hepatocytes, 1% of normal liver enzyme activity, and a reduction in lysosomal storage in the liver at 3.5 months. Surprisingly, controls that received retroviral vector without HGF had transduction of nonparenchymal cells in the liver, significant levels of enzyme and RNA in the liver at 2 but not 3.5 months, and reduced lysosomal storage at 3.5 months. Transduction was also achieved in the replicating cells of the spleen, where lysosomal storage was reduced. An approach using a retroviral vector without a growth factor might temporarily reduce lysosomal storage in the liver and spleen in humans. Addition of HGF might be used to augment and prolong gene transfer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10985954     DOI: 10.1006/mthe.2000.0121

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  8 in total

Review 1.  Gene therapy for mucopolysaccharidosis.

Authors:  Katherine P Ponder; Mark E Haskins
Journal:  Expert Opin Biol Ther       Date:  2007-09       Impact factor: 4.388

2.  Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy.

Authors:  Glenn P Niemeyer; Roland W Herzog; Jane Mount; Valder R Arruda; D Michael Tillson; John Hathcock; Frederik W van Ginkel; Katherine A High; Clinton D Lothrop
Journal:  Blood       Date:  2008-10-28       Impact factor: 22.113

3.  Active site mutant transgene confers tolerance to human beta-glucuronidase without affecting the phenotype of MPS VII mice.

Authors:  W S Sly; C Vogler; J H Grubb; M Zhou; J Jiang; X Y Zhou; S Tomatsu; Y Bi; E M Snella
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

4.  Production of MPS VII mouse (Gus(tm(hE540A x mE536A)Sly)) doubly tolerant to human and mouse beta-glucuronidase.

Authors:  Shunji Tomatsu; Koji O Orii; Carole Vogler; Jeffrey H Grubb; Elizabeth M Snella; Monica Gutierrez; Tatiana Dieter; Christopher C Holden; Kazuko Sukegawa; Tadao Orii; Naomi Kondo; William S Sly
Journal:  Hum Mol Genet       Date:  2003-05-01       Impact factor: 6.150

5.  Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs.

Authors:  Katherine Parker Ponder; John R Melniczek; Lingfei Xu; Margaret A Weil; Thomas M O'Malley; Patricia A O'Donnell; Van W Knox; Gustavo D Aguirre; Hamutal Mazrier; N Matthew Ellinwood; Meg Sleeper; Albert M Maguire; Susan W Volk; Robert L Mango; Jean Zweigle; John H Wolfe; Mark E Haskins
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-13       Impact factor: 11.205

6.  A self-inactivating gamma-retroviral vector reduces manifestations of mucopolysaccharidosis I in mice.

Authors:  Jason A Metcalf; Xiucui Ma; Bruce Linders; Susan Wu; Axel Schambach; Kevin K Ohlemiller; Attila Kovacs; Mark Bigg; Li He; Douglas M Tollefsen; Katherine P Ponder
Journal:  Mol Ther       Date:  2009-10-20       Impact factor: 11.454

7.  Clinical response to persistent, low-level beta-glucuronidase expression in the murine model of mucopolysaccharidosis type VII.

Authors:  A Donsante; B Levy; C Vogler; M S Sands
Journal:  J Inherit Metab Dis       Date:  2007-02-16       Impact factor: 4.750

8.  Effects of gene therapy on cardiovascular symptoms of lysosomal storage diseases.

Authors:  Edina Poletto; Gabriela Pasqualim; Roberto Giugliani; Ursula Matte; Guilherme Baldo
Journal:  Genet Mol Biol       Date:  2019-05-23       Impact factor: 1.771

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.